Search
forLearn
5 / 801 resultslearn Beta Polypeptide
learn Gluco peptide
learn Aminobutyric Acid
learn ppg-26-buteth-26
Research
5 / 1000+ results
research Mendelian Randomization Identifies CD25+ CD4+ Tregs and Plasma Proteins in Androgenetic Alopecia Pathogenesis
CD25+ CD4+ Tregs and certain plasma proteins are linked to hair loss.
research Pharmacodynamics of minoxidil as a guide for individualizing dosage regimens in hypertension
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
research PIK3CA gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect
A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.
research Adverse effects of finasteride in men treated for benign prostatic hyperplasia and androgenetic alopecia - a literature review
Finasteride can cause sexual and psychological side effects, but these usually reverse after stopping the medication.
Community Join
5 / 1000+ resultscommunity IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community IGE Hair Loss and Miniaturization
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Interesting new publication suggesting that MPB should be assessed as a early warning sign for type-2 diabetes.
Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.